


CLAIMS

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



5

wherein


one of X and Y is N and the other is C;

L is a linker group selected from a bond or $-(CH_2)_a-Q-(CH_2)_b-$ in which, Q is selected from the group comprising: O, NH, SO_2 , $C=C$, and $C\equiv C$ or Q is absent;

- 10 R^1 is a 6 membered monocyclic aromatic, carbocyclic, heteroaromatic or heterocyclic ring substituted by one R^3 group, R^1 may be further substituted with 0 or 1 groups selected from halo, C_{1-6} alkyl, or C_{1-6} haloalkyl;

R^2 is $-C(O)OH$ or $-C(O)OM$; wherein M is a group 1 cation;

- R^3 is selected from the group comprising: $-CONR^4(CR^aR^b)_nNR^5R^6$, -
 15 $CONR^4(CR^aR^b)_nOSO_2OR^5$, $-CONR^4(CR^aR^b)_nCN$, $-CONR^4(CR^aR^b)_nC(=O)OH$, -
 $CONR^4(CR^aR^b)_nC(=O)NR^7R^8$, $-NR^4CO(CR^aR^b)_nNR^7R^8$, $-NR^4CO(CR^aR^b)_nOSO_2OR^5$, -
 $NR^4CO(CR^aR^b)_nCN$, $-NR^4CO(CR^aR^b)_nC(=O)OH$, $-NR^4CO(CR^aR^b)_nC(=O)NR^7R^8$, -
 $SO_2NR^4(CR^aR^b)_nNR^5R^6$, $-SO_2NR^4(CR^aR^b)_nOSO_2OR^5$, $-SO_2NR^4(CR^aR^b)_nCN$, -
 $SO_2NR^4(CR^aR^b)_nC(=O)OH$, $-SO_2NR^4(CR^aR^b)_nC(=O)NR^7R^8$,



R⁴ is selected at each occurrence from the group comprising: H, halo, -OH, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, C₃₋₈ cycloalkenyl, -(CH₂)_r-aryl, -(CH₂)_d-heteroaryl, -(CH₂)_g-heterocyclyl; wherein R⁴ may be optionally substituted where chemically possible with one, two or three groups independently selected at each occurrence from the group comprising: halo, -NH₂, -N(C₁₋₄ alkyl)₂, -OH, -SO₂N(C₁₋₄ alkyl)₂, -NHC(=O)OC₁₋₆ alkyl and -C(=O)OC₁₋₆ alkyl;

R⁵ and R⁶ are each independently H or C₁₋₆ alkyl;

wherein at least one of R⁴, R⁵ or R⁶ is C₁₋₆ alkyl when each of R⁴, R⁵ and R⁶ are present;

R⁷ and R⁸ are each independently selected at each occurrence from H or C₁₋₄ alkyl;

R⁹ is selected from the group comprising: H, C₁₋₄ alkyl, and C₁₋₄ haloalkyl;

R^a and R^b are each independently selected at each occurrence from: H, halo, -NH₂, and C₁₋₄ alkyl;

a, b, d, f and g are independently selected as integers from 0 to 3;


m is an integer selected from 1, 2 or 3;

n is an integer selected from 1, 2, 3, 4 or 5; and


-- represents a single or a double bond as required to satisfy valence requirements.


2. A compound according to claim 1, wherein Y is N and X is C.


3. A compound according to claim 1 or claim 2, wherein R³ is selected from the group comprising: -CONR⁴(CR^aR^b)_nNR⁵R⁶, -CONR⁴(CR^aR^b)_nOSO₂OR⁵, -CONR⁴(CR^aR^b)_nCN, -CONR⁴(CR^aR^b)_nC(=O)OH, -CONR⁴(CR^aR^b)_nC(=O)NR⁷R⁸,





4. A compound as claimed in any preceding claim, wherein R^3 is selected from: -
 $\text{CONH}(\text{CH}_2)_2\text{NHMe}$, $-\text{CON}(\text{Me})(\text{CH}_2)_2\text{NHMe}$, $-\text{CONH}(\text{CH}_2)_3\text{NHMe}$, $-\text{CON}(\text{Me})(\text{CH}_2)_2\text{NHMe}$,
5 $-\text{CONH}(\text{CH}_2)_3\text{OSO}_2\text{OH}$, $-\text{CON}(\text{Me})(\text{CH}_2)_3\text{OSO}_2\text{OH}$, $-\text{CONH}(\text{CH}_2)_3\text{OSO}_2\text{OMe}$,
 $\text{CON}(\text{Me})(\text{CH}_2)_3\text{OSO}_2\text{OMe}$, $-\text{CONHCH}_2\text{CN}$, $-\text{CONH}(\text{CH}_2)_2\text{CN}$, $-\text{CON}(\text{Me})\text{CH}_2\text{CN}$,
 $\text{CON}(\text{Me})(\text{CH}_2)_2\text{CN}$, $-\text{CONH}(\text{CH}_2)_2\text{C}(=\text{O})\text{OH}$, $-\text{CON}(\text{Me})(\text{CH}_2)_2\text{C}(=\text{O})\text{OH}$,
 $\text{CONHCH}_2\text{C}(=\text{O})\text{OH}$, $-\text{CON}(\text{Me})\text{CH}_2\text{C}(=\text{O})\text{OH}$, $-\text{CONHCH}_2\text{C}(=\text{O})\text{NH}_2$,
 $\text{CONMeCH}_2\text{C}(=\text{O})\text{NH}_2$, $-\text{CONHCH}_2\text{C}(=\text{O})\text{NHMe}$, $-\text{CONMeCH}_2\text{C}(=\text{O})\text{NHMe}$,
10 $\text{CONH}(\text{CH}_2)_2\text{C}(=\text{O})\text{NH}_2$, $-\text{CONMe}(\text{CH}_2)_2\text{C}(=\text{O})\text{NH}_2$, $-\text{CONH}(\text{CH}_2)_2\text{C}(=\text{O})\text{NHMe}$,
 $\text{CONMe}(\text{CH}_2)_2\text{C}(=\text{O})\text{NHMe}$.
5. A compound as claimed in any preceding claim, wherein R^4 is selected at each occurrence from the group comprising: H, halo, substituted or unsubstituted C_{1-6} alkyl, and substituted or unsubstituted C_{3-8} cycloalkyl.
- 15 6. A compound as claimed in claim 5, wherein R^4 is independently selected at each occurrence from H and Me.
7. A compound as claimed in claim 6, wherein R^5 and R^6 are each independently selected from the group comprising: H, Me, Et, $n\text{Pr}$, $i\text{Pr}$ and $n\text{Bu}$.
8. A compound as claimed in any preceding claim, wherein R^5 and R^6 are each
20 independently H or Me.
9. A compound as claimed in claim 1, wherein the compound is selected from:
















10. A compound selected from:






















11. A compound selected from:














12. A pharmaceutical composition which comprises a compound of any preceding claim, or
 5 a pharmaceutically acceptable salt, hydrate or solvate thereof, in association with one or more pharmaceutically acceptable excipients.

13. A compound of any of claims 1 to 11, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a formulation as claimed in claim 14, for use in the inhibition of metallo- β -lactamase activity.

14. A compound of any of claims 1 to 11, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a composition as claimed in claim 12, for use in the treatment of a disease or disorder in which metallo- β -lactamase activity is implicated.
15. A compound of any of claims 1 to 11, or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in a method of treating a disease or disorder caused by aerobic or anaerobic Gram-positive, or aerobic or anaerobic Gram-negative bacteria.
16. The compound for use of claim 15 wherein the disease or disorder is caused by metallo- β -lactamase producing Gram-positive bacteria.
17. The compound for use of claim 15 or 16 wherein the disease or disorder is selected from: pneumonia, respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections, bloodstream infections, septicaemia, intra- and post-partum infections, prosthetic joint infections, endocarditis, acute bacterial meningitis and febrile neutropenia.
18. The compound for use of claim 17 in the treatment of a disease or disorder selected from: community acquired pneumonia, nosocomial pneumonia (hospital-acquired/ventilator-acquired), respiratory tract infections associated with cystic fibrosis, non-cystic fibrosis bronchiectasis, COPD, urinary tract infection, intra-abdominal infections, skin and soft tissue infection, bacteraemia, septicaemia, intra- and post-partum infections, prosthetic joint infections, endocarditis, acute bacterial meningitis and febrile neutropenia.
19. The compound for use of claim 18 in the treatment of a disease or disorder selected from: community acquired pneumonia, nosocomial pneumonia (hospital-acquired/ventilator-acquired), respiratory tract infections associated with cystic fibrosis, non-cystic fibrosis bronchiectasis, COPD, urinary tract infection, intra-abdominal infections, skin and soft tissue infection, bacteraemia and septicaemia.
20. A compound of any of claims 1 to 11, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a formulation as claimed in claim 12, for use in the treatment of a bacterial infection.
21. A compound of any of claims 1 to 11, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a formulation as claimed in claim 12, in combination with an antibacterial agent, for use in the treatment of a bacterial infection.

22. A compound as claimed in claim 21, wherein the compound and the antibacterial agent are presented in the same dosage forms.

23. A compound as claimed in claim 21 or 22, wherein the antibacterial agent is a carbapenem, and preferably the carbapenems is selected from the group comprising:
5 meropenem, faropenem, imipenem, ertapenem, doripenem, panipenem/betamipron and biapenem, razupenem, tebipenem, lenapenem and tomopenem.

24. A compound as claimed in claim 23, wherein the antibacterial agent is meropenem.

25. A compound as claimed in any of claims 20 to 24, wherein the bacterial infection is caused by bacteria from one or more of the following families; *Streptococcus*,
10 *Acinetobacter*, *Staphylococcus*, *Clostridioides*, *Pseudomonas*, *Escherichia*, *Salmonella*, *Klebsiella*, *Legionella*, *Neisseria*, *Enterococcus*, *Enterobacter*, *Serratia*, *Stenotrophomonas*, *Aeromonas*, *Mycobacterium*, *Morganella*, *Yersinia*, *Pasteurella*, *Haemophilus*, *Citrobacter*, *Burkholderia*, *Brucella*, or *Moraxella*.

26. A method for the prevention or treatment of bacterial infection in a patient in need of
15 such treatment, said method comprising administering to said patient a therapeutically effective amount of a combination of an antibacterial agent with a compound of in any of claims 1 to 11, or a pharmaceutically acceptable salt, hydrate or solvate thereof; or administering to said patient a therapeutically effective amount of an antibacterial agent in combination with a pharmaceutical composition, as claimed in claim 12, containing a
20 compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate thereof.

27. A method for the prevention or treatment of a disease or disorder, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of a combination of an antibacterial agent with a compound of any of claims 1 to 11, or a pharmaceutically acceptable salt, hydrate or solvate thereof; or administering to
25 said patient a therapeutically effective amount of an antibacterial agent in combination with a pharmaceutical composition as claimed claim 12, containing a compound of or a pharmaceutically acceptable salt, hydrate or solvate thereof.

28. The method of claim 27, wherein the disease or disorder is caused by aerobic or anaerobic Gram-positive, or aerobic or anaerobic Gram-negative bacteria.

29. The method of claim 28, wherein the disease or disorder is caused by metallo- β -lactamase producing Gram-positive bacteria.

30. The method of claim 28 or 29, wherein the disease or disorder is selected from: pneumonia, respiratory tract infections, urinary tract infections, intra-abdominal infections,
5 skin and soft tissue infections, bloodstream infections, septicaemia, intra- and post-partum infections, prosthetic joint infections, endocarditis, acute bacterial meningitis and febrile neutropenia.

31. The method of claim 30, wherein the disease or disorder is selected from: community acquired pneumonia, nosocomial pneumonia (hospital-acquired/ventilator-acquired),
10 respiratory tract infections associated with cystic fibrosis, non-cystic fibrosis bronchiectasis, COPD, urinary tract infection, intra-abdominal infections, skin and soft tissue infection, bacteraemia, septicaemia, intra- and post-partum infections, prosthetic joint infections, endocarditis, acute bacterial meningitis and febrile neutropenia.

32. The method of claim 31, wherein the disease or disorder is selected from: community
15 acquired pneumonia, nosocomial pneumonia (hospital-acquired/ventilator-acquired), respiratory tract infections associated with cystic fibrosis, non-cystic fibrosis bronchiectasis, COPD, urinary tract infection, intra-abdominal infections, skin and soft tissue infection, bacteraemia and septicaemia.

20